Acetaminophen Market to be worth US$ 14.07 Billion by the year 2031 - Comprehensive Research Report by FMI
Future Market Insights Global and Consulting Pvt. Ltd.
Future Market Insights Global and Consulting Pvt. Ltd.

Acetaminophen Market - Analysis, Outlook, Growth, Trends, Forecasts

DUBAI, United Arab Emirates, March 06, 2022 (GLOBE NEWSWIRE) -- Acetaminophen Market is expected to reach US$ 14.07 Bn by 2031, expanding at a 4.1% CAGR over the assessment period 2021-2031.

According to a recent study by Future Market Insights (FMI), the global acetaminophen market is expected to grow from US$ 9.4 Bn in 2021, to over US$ 14.1 Bn by 2031, expanding at a 4.1% CAGR over the forecast period 2021-2031.

Data Points

Market Insights

Acetaminophen Market Value 2021

US$ 9.44 Bn

Acetaminophen Market Value 2031

US$ 14.06 Bn

Acetaminophen Market Value-based CAGR 2021-2031

4.1%

Acetaminophen Market Top 5 Countries % Share

58.2%

Acetaminophen Market Key Players

Abbott, Janssen Pharmaceuticals, Inc. [Johnson & Johnson], Bristol-Myers Squibb and Company, Cardinal Health Inc., Viatris, Procter & Gamble Company, Sanofi, Novartis AG, Bayer AG, Teva Pharmaceutical Industries Ltd, Perrigo Company, Mallinckrodt Pharmaceuticals, Glaxo SmithKline Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd.

Request a report sample to gain comprehensive insights at https://www.futuremarketinsights.com/reports/sample/rep-gb-14325

Acetaminophen/ paracetamol is widely being adopted by individuals and healthcare providers and are sold over the counter, which is boosting sales in the market. Paracetamol is widely consumed as it is suitable to all age groups i.e. adults, children’s, pediatrics and geriatrics to treat mild to moderate pain. Paracetamol is the most efficient and safe drug to manage pain when consumed in a controlled dosage.

The most prescribed OTC (over the counter) drug is acetaminophen, which is widely used as the first line of treatment. As chronic disorders have symptoms of pain, demand is projected to increase over the forecast period.

According to the CDC, in 2019, 20.4% of adults had chronic pain and 7.4% of adults had chronic pain that frequently limited life or work activities. Similarly, in the U.K., around 26% of patients with diabetes were found to have peripheral neuropathic pain. Paracetamol can be combined with other pain management drugs that are sold through prescription only, which is expected to continue boosting sales.

Further, increasing awareness regarding palliative care in terminally ill patients is boosting the adoption of analgesics for pain management. Since the prevalence of pain is over 75% in advanced disease conditions, sales are expected to gain traction in the forthcoming years.

In the U.S., palliative care services are delivered following government and commercial reimbursement policies. Hospital palliative care programs in the U.S. include palliative care consultation teams and dedicated in-patient care units. Non-hospital palliative care programs include ambulatory care, and office and home-based palliative care programs.